June 19, 2026
XX
min read

Freedom-to-Operate for GLP-1 and Peptide Therapeutics in 2026

Writen By:

Cypris Research Team

Register here

Subscribe to receive the latest blog posts to your inbox every week.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Freedom-to-operate for GLP-1 receptor agonists and peptide therapeutics is among the most demanding FTO problems in pharmaceuticals, because protection in this class is built as a dense, layered thicket that extends far beyond the active ingredient. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims. In the GLP-1 and peptide space, answering that question requires reading many claim types across many patents, because a single product is protected by a stack of filings covering the molecule, its formulation, its dosing, its delivery device, and its manufacture. A peer-reviewed analysis of GLP-1 receptor agonists approved between 2005 and 2021 found that manufacturers listed a median of 19.5 patents per product, that 54 percent of those patents were on delivery devices rather than the active ingredient, that the median expected protection was 18.3 years after approval, and that no generic manufacturer had yet successfully challenged a GLP-1 receptor agonist patent.¹

The commercial stakes are large. Industry analyst forecasts vary widely with scope, placing the GLP-1 market anywhere from the low tens of billions of dollars to well over one hundred billion by 2030 and projecting double-digit annual growth; these are analyst estimates rather than authoritative figures, and they differ mainly in what they count.² The scale of the opportunity is what drives the density of the patent thicket, because each additional protected feature can delay competition on a high-revenue product. For any organization developing a follow-on peptide, a biosimilar, or a differentiated GLP-1 product, FTO is therefore a gating analysis rather than a formality.

Peptide therapeutics compound the difficulty. Peptides can be claimed as sequences and modifications, formulated for stability and half-life extension, delivered by injection or increasingly by oral routes, and manufactured through distinct synthesis and purification processes, so the claim surface is broad. Recent filing activity has shifted toward oral delivery, dual and triple receptor agonists, and combination therapies, which is where both the newest FTO risk and the remaining white space now sit.³ An FTO analysis in this class has to cover all of these dimensions, and it has to stay current as the frontier moves.

What creates FTO risk in GLP-1 and peptide products

Composition-of-matter claims. These cover the peptide itself, including sequences, analogues, and modifications, and are the primary protection, though in a mature class many core molecules approach expiry.

Formulation claims. These cover stabilized, extended-release, and oral formulations, which are heavily patented, as formulation is where much peptide innovation and differentiation occurs.

Dosing-regimen and method-of-use claims. These cover titration schedules and specific therapeutic uses, and can block a product for a particular indication or regimen even when the molecule is otherwise available.

Delivery-device claims. These cover injection pens and other devices and are a large share of the thicket; peer-reviewed analysis found delivery devices accounted for the majority of listed GLP-1 patents and function as a distinct barrier to entry.¹,⁴

Process and manufacturing claims. These cover synthesis and purification routes, so a developer can be free to use a molecule yet blocked from a particular manufacturing method.

A single molecule illustrates the layering. A published patent landscape of one dual GLP-1/glucagon receptor agonist identified twelve patent families spanning composition-of-matter, process chemistry, formulation, dosing regimen, and method-of-use, a clean worked example of how all five claim types stack on one product.⁵

The thicket dynamic and the expiry landscape

The density of GLP-1 protection reflects a broader pharmaceutical pattern. Empirical analysis shows the number of patents filed per active ingredient rose from 1.86 in 2001 to nearly six by 2019, driven substantially by continuation applications, which account for roughly a third of small-molecule pharmaceutical patents.⁶ These secondary filings extend the effective protection period, and the economics of that extension, including how patent challenges and settlements shape effective market life, are well documented.⁷ Pharmaceutical thickets also differ structurally from thickets in complex-technology industries, which is why FTO methods developed for electronics do not transfer cleanly to peptides.⁸

The expiry landscape is the other half of the picture. As core molecules approach the end of composition-of-matter protection, the surrounding formulation, device, and process claims determine when and where competition can actually enter. Analysis of one leading GLP-1 molecule found that the timing of primary-patent expiry varies substantially by market, so freedom-to-operate for a follow-on product is jurisdiction-specific, and the practical entry date is governed by the secondary thicket rather than the headline molecule expiry.⁹ For a developer, this means FTO must be assessed claim-by-claim and market-by-market, not at the level of the molecule.

How AI-powered FTO helps

Navigating a thicket of this density by manual search is slow and prone to coverage gaps, which are the main source of FTO risk. AI-powered FTO addresses this with semantic search that retrieves relevant claims regardless of terminology, claim-level analysis that focuses on the independent claims defining infringement scope across all five claim types, and continuous monitoring that keeps a cleared position current as new formulation, device, and combination filings publish. Because peptide innovation appears in scientific literature before it is patented, reading both patents and literature gives earlier warning of where the thicket is extending.

Where Cypris fits

Cypris runs claim-level, semantic, AI-powered freedom-to-operate across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology, across composition, formulation, dosing-regimen, delivery-device, and process claims, which is what a dense peptide thicket demands. The ontology clusters the thicket by concept and normalizes assignees, so a team sees the structure of protection around a molecule rather than a flat list. Cypris Q, the platform's agentic layer, lets teams run and chain FTO analysis conversationally, and Agentic Monitoring tracks a molecule and its surrounding thicket over time, flagging new formulation, device, and combination filings as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for GLP-1 and peptide therapeutics?

Freedom-to-operate is hard for GLP-1 and peptide therapeutics because protection is built as a dense, layered thicket extending well beyond the active ingredient. A peer-reviewed analysis found GLP-1 products carry a median of 19.5 listed patents each, most of them on delivery devices. Assessing FTO requires reading composition, formulation, dosing, device, and process claims across many patents and markets.

What claim types create FTO risk for GLP-1 products?

Five claim types create FTO risk for GLP-1 products: composition-of-matter claims on the peptide, formulation claims on stabilized and oral forms, dosing-regimen and method-of-use claims, delivery-device claims, and process or manufacturing claims. Each can independently block a product. Delivery-device claims are a particularly large share of the GLP-1 thicket.

How many patents protect a typical GLP-1 product?

A peer-reviewed analysis of GLP-1 receptor agonists approved between 2005 and 2021 found a median of 19.5 listed patents per product, with 54 percent on delivery devices rather than the active ingredient, and a median of 18.3 years of expected protection after approval. No generic manufacturer had successfully challenged a GLP-1 receptor agonist patent as of that analysis. These figures illustrate the density of the thicket.

What is a pharmaceutical patent thicket?

A pharmaceutical patent thicket is a dense set of overlapping patents around a single product that extends protection beyond the core molecule. Empirical analysis shows patents per active ingredient rose from 1.86 in 2001 to nearly six by 2019, driven substantially by continuation applications. Thickets shape when and where competition can enter.

How does the expiry of GLP-1 patents affect freedom-to-operate?

The expiry of GLP-1 patents affects freedom-to-operate market-by-market, because primary-patent expiry timing varies by jurisdiction and the practical entry date is governed by the surrounding formulation, device, and process claims rather than the molecule alone. FTO must therefore be assessed claim-by-claim and market-by-market. A molecule can be off-patent in one country and still protected in another.

Where is the white space in GLP-1 and peptide development?

Recent filing activity has shifted toward oral delivery, dual and triple receptor agonists, and combination therapies, which is where both new FTO risk and remaining white space now sit. Mapping this frontier requires reading patents and scientific literature together, since peptide innovation appears in research first. White space analysis identifies the areas that are still open.

How does AI-powered FTO help with peptide therapeutics?

AI-powered FTO helps with peptide therapeutics by using semantic search to retrieve relevant claims regardless of terminology, claim-level analysis to focus on the independent claims that define infringement across all claim types, and continuous monitoring to keep a cleared position current. This is what a dense, fast-moving thicket requires. Cypris runs this across more than 500 million patents and scientific papers.

Which teams need GLP-1 and peptide FTO analysis?

GLP-1 and peptide FTO analysis is needed by pharmaceutical and biotech R&D, IP, and business-development teams developing follow-on peptides, biosimilars, differentiated formulations, or combination products. It is also relevant to generics manufacturers assessing entry. Cypris serves hundreds of enterprise customers across pharmaceuticals and other regulated industries.

How current does GLP-1 FTO need to be?

GLP-1 FTO needs to be continuously current, because new formulation, device, dosing, and combination filings publish constantly and can change a cleared position. A one-time assessment reflects only the moment it was run. Cypris uses Agentic Monitoring to track a molecule and its surrounding thicket over time and flag new filings as they publish.

Endnotes

  1. Tu, S. S., Feldman, W. B., Alhiary, R., Gabriele, S., Kesselheim, A. S. & Beall, R. F. (2023). Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists. JAMA. https://doi.org/10.1001/jama.2023.13872
  2. Industry analyst estimates (e.g., Research and Markets; BCC Research). GLP-1 market forecasts vary widely by scope and are presented here as order-of-magnitude estimates, not authoritative figures.
  3. Han, J., Zhou, Z., Jiang, N. & Lu, W. (2023). An updated patent review of GLP-1 receptor agonists (2020–present). Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2023.2274905
  4. Tu, S. S., Feldman, W. B. et al. (2024). Delivery Device Patents on GLP-1 Receptor Agonists. JAMA. https://doi.org/10.1001/jama.2024.0919
  5. Fasi, M. A. (2026). Patent landscape and therapeutic evolution of mazdutide. Expert Opinion on Therapeutic Patents. https://doi.org/10.1080/13543776.2026.2645812
  6. Tu, S. S. (2024). The Long CON: An Empirical Analysis of Pharmaceutical Patent Thickets. University of Pittsburgh Law Review. https://doi.org/10.5195/lawreview.2024.1049
  7. Hemphill, C. S. & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics. https://doi.org/10.1016/j.jhealeco.2012.01.004
  8. Tu, S. S. & Carrier, M. A. (2023). Why Pharmaceutical Patent Thickets Are Unique. SSRN. https://doi.org/10.2139/ssrn.4571486
  9. Ramesh, S., Cross, S., Levi, J., Hill, A. & Venter, F. (2026). How Low Could Semaglutide Prices Fall? Implications for Global Access Ahead of Patent Expiry. Obesity. https://doi.org/10.1002/oby.70241

Keep Reading

July 16, 2026
XX
min read
What Is an MCP Server? How the Model Context Protocol Works for Patent Search and R&D Intelligence
Blogs
July 15, 2026
XX
min read
Solid-State Battery Electrolyte Patent Landscape: Sulfide vs. Oxide vs. Polymer in 2026
Blogs
July 14, 2026
XX
min read
Semantic Search for Patents: How It Works and Why It Outperforms Keyword Search in 2026
Blogs